摘要
Abstract
Objective:To investigate the effect of different doses of rosuvastatin in patients with acute ST-segmert elevation myocardial infarction (STEMI) who underwent percutaneous coronary intervention (PCI).Methods:180 patients with STEMI undergoing PCI were selected and randomly divided into an observation group and a control group,with 90 cases in each group.The patients in the observation group were treated with 20 mg rosuvastatin before and after PCI,and those in the control group were treated with 10 mg rosuvastatin before and after PCI.The levels of total cholesterol (TC),triglyceride (TG),low density lipoprotein (LDL-C),high density lipoprotein (HDL-C),creatinine (Cr),creatine kinase-MB (CK-MB),troponin I (cTnI),brain natriuretic peptide (BNP) were measured before and 7 days after PCI.Anterior descending branch (LAD),left cyclotron (LCX),and right coronary artery (RCA) perfusion were assessed.The clinical effect,thrombolysis in myocardial infarction (TIMI) trial and the incidence of adverse events were observed and compared between the two groups.Results:After treatment,the levels of TC,TG,LDL-C,CK-MB,cTnI and BNP were decreased,while the HDL-C and Cr levels were increased in the observation group,compared with the control group (P＜0.05).No significant differences between groups were observed for the LAD,LCX and RCA perfusion (P＞ 0.05).Lower percentage of patients with TIMI grade 2,ard higher percentage of TIMI grades 3 were found in the observation group (P＞0.05).30 days after treatment,the left ventricular ejection fraction (LVEF) was higher,and the left ventricular diastolic endoscopy (LVEDD) was lower in the observation group than those in the control group.No severe adverse events were noted in both groups during therapy.Conclusion:Higher dose of rosuvastatin could effectively promote myocardial perfusion in STEMI patients undergoing PCI,reduce myocardial injury and improve cardiac function.关键词
急性ST段抬高型心肌梗死/介入治疗/瑞舒伐他汀Key words
acute ST-segment elevation myocardial infarction/interventional therapy/rosuvastatin分类
医药卫生
